

Roxyfoli-50

Roxithromycin IP 50mg.



Broad Spectrum Activity

Effective against a wide range of Gram-positive and atypical respiratory pathogens.¹



Excellent Tissue Penetration

Achieves high concentrations in respiratory tissues for enhanced therapeutic success.²



Ideal for Respiratory Infections

Highly effective in sinusitis, bronchitis, pharyngitis, and community-acquired pneumonia.³



Well Tolerated

Lower incidence of GI side effects compared to other macrolides.⁴



Convenient Dosing

Once or twice daily dosing ensures better patient compliance.⁵



INDICATIONS



Acute Bronchitis



Acute Sinusitis



Pharyngitis/
Tonsillitis



Community Acquired
Pneumonia



Otitis Media



Skin & Soft Tissue
Infections

References:

1. Petty MC. Drugs. 1992;44(1):72-90.

2. Blondeau JM, et al. J Antimicrob Chemother. 199-bld 44(Suppl B):21-30.

3. File TM Jr, et al. Clin Infect Dis. 2001;33(Suppl 3):S187-S196.

4. Dunne MW, et al. J Antimicrob Chemother. 1993;31(Suppl A):73-84.

5. Giamarellou H. J Chemother. 1998;10(Suppl 4):5-12.